Massachusetts Financial Services Co. MA cut its stake in shares of TransMedics Group Inc (NASDAQ:TMDX) by 0.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 368,013 shares of the company’s stock after selling 1,374 shares during the period. Massachusetts Financial Services Co. MA’s holdings in TransMedics Group were worth $8,740,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently made changes to their positions in the business. NumerixS Investment Technologies Inc purchased a new stake in TransMedics Group during the 2nd quarter valued at $43,000. JPMorgan Chase & Co. purchased a new stake in TransMedics Group during the 2nd quarter valued at $50,000. Tower Research Capital LLC TRC purchased a new stake in TransMedics Group during the 2nd quarter valued at $190,000. Blackstone Group Inc purchased a new stake in TransMedics Group during the 2nd quarter valued at $290,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in TransMedics Group during the 2nd quarter valued at $314,000. Institutional investors and hedge funds own 65.84% of the company’s stock.
Shares of TMDX opened at $18.31 on Monday. The company has a quick ratio of 6.82, a current ratio of 7.33 and a debt-to-equity ratio of 0.54. The company’s fifty day moving average is $18.71. TransMedics Group Inc has a 1-year low of $15.74 and a 1-year high of $31.54.
A number of equities research analysts have weighed in on TMDX shares. Zacks Investment Research upgraded shares of TransMedics Group from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Cowen decreased their target price on shares of TransMedics Group from $40.00 to $28.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $33.00.
In related news, Director David Weill acquired 10,000 shares of TransMedics Group stock in a transaction dated Monday, November 11th. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $170,000.00. Following the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $170,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
TransMedics Group Company Profile
TransMedics, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation.
Featured Article: Options Trading
Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group Inc (NASDAQ:TMDX).
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.